The Russian innovative drug Aviandr® has been included in the international pharmaceutical register of the World Health Organization (WHO)

Avineiro, a company of the ChemRar group, the owner of the registration certificate for the drug Aviandr®, announces that the active ingredient of the drug has been assigned the international non-proprietary name (INN) Maritupirdine. This is an official recognition of the uniqueness and innovation of the Russian molecule and its inclusion in the international pharmaceutical register of the World Health Organization.

Aviandr® (maritupirdine) is a modern anxiolytic with multitarget activity, intended for the treatment of generalized anxiety disorder, as well as anxiety states associated with adaptation disorders after COVID-19. The drug has a pronounced anti-anxiety and antidepressant effect, reducing the symptoms already from the first week of admission.

In clinical trials conducted at leading Russian medical centers, Aviandr® demonstrated high efficacy and good tolerability, including in elderly patients. At the same time, there was no pronounced sedation, withdrawal syndrome or addiction, as well as the endocrine system side effects typical for many antidepressants (including weight gain).

According to the World Health Organization, anxiety disorders remain the most common type of mental illness, affecting approximately 4% of the global population. In recent years, particularly in the context of global events characterized by high levels of uncertainty, emotional stress, and information overload, as well as the COVID-19 pandemic, the prevalence of anxiety and depressive disorders has increased by 25% worldwide.
This highlights the importance of timely diagnosis and access to effective treatments for anxiety disorders in the face of ongoing global and local stressors.

In Russia, as in the rest of the world, there has been a steady increase in the number of people seeking medical help for anxiety disorders. This is not only a medical issue, but also a socio-economic one, as anxiety disorders can significantly impact quality of life, work performance, and require timely diagnosis and treatment.

The assignment of the INN maritupirdine confirms the originality and innovation of the domestic drug Aviandr®, and also opens up new opportunities for its international recognition and application in the treatment of anxiety and depressive disorders. The drug Aviandr® (maritupirdine) is prescribed by a doctor’s prescription. There are contraindications.

The ChemRar Group unites research and production organizations in the field of development of innovative medicines, diagnostics, prevention and new methods of treatment of life-threatening diseases in Russia and abroad.